Gold Prices Steady as Markets Await Key U.S. Data and Expected Fed Rate Cut 
Citi Sets Bullish 2026 Target for STOXX 600 as Fiscal Support and Monetary Easing Boost Outlook 
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
Australia’s Economic Growth Slows in Q3 Despite Strong Investment Activity 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Asian Currencies Edge Higher as Markets Look to Fed Rate Cut; Rupee Steadies Near Record Lows 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
Asian Currencies Steady as Markets Await Fed Rate Decision; Indian Rupee Hits New Record Low 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
Asian Markets Mixed as Fed Rate Cut Bets Grow and Japan’s Nikkei Leads Gains 
USPS Expands Electric Vehicle Fleet as Nationwide Transition Accelerates 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
Japan’s Nikkei Drops as Markets Await Key U.S. Inflation Data 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
Pfizer Inc.’s planned delivery of critical new medicines, such as respiratory syncytial virus (RSV) vaccine, to low-income nations, is likely to be delayed by several years due to several issues.
According to global health officials, Pfizer has not yet taken some of the necessary actions to make the vaccine accessible in developing nations.
They include getting the shot approved by the WHO and by nonprofit organizations that finance purchases in low-income countries, such as the global vaccine alliance Gavi.
Furthermore, the health agency prefers syringes that are automatically disabled after one injection for safety reasons to prevent reuse, but Pfizer's RSV vaccine is not made for those syringes.
Additionally, the RSV shot is only presently offered in single-dose vials. Multi-dose vials are frequently utilized in situations with less resources since they are less expensive and easier to distribute.
Preservatives must be added to multi-dose vials, therefore the manufacturer must do further tests to make sure there will be no impact on the vaccine's safety or effectiveness.
The vaccine will need a different delivery system to be used in developing countries in Africa and Asia, including alternative packaging and syringes.
Preparations for those modifications are just beginning, according to the World Health Organization.
Pfizer committed to more equitable access last year, following criticism that it prioritized wealthy nations for doses of its COVID-19 shot early in the pandemic. The company says it wants to shorten a timeline in which poorer countries often get vaccines many years after they are available elsewhere.
The drugmaker received a $28 million grant from the Bill and Melinda Gates Foundation in September to support the launch of the RSV vaccine in poorer countries, where RSV, a common cold-like virus, is much more likely to be lethal for very young children.
Pfizer's maternal RSV vaccine is expected to be approved for use in pregnant women in August in the US and several months later in Europe. Its peak sales forecast is more than $2 billion annually, together with the maternal vaccine and an RSV shot for older adults.
